Design Therapeutics, Inc. Debt/Equity

Debt/Equity of DSGN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Debt/Equity growth rates and interactive chart. The debt-to-equity (D/E) ratio is calculated by dividing a company's total interest-bearing liabilities by its shareholder equity. These numbers are available on the balance sheet of a company's financial statements. The ratio is used to evaluate a company's financial leverage. The debt/equity ratio can be compared to a company's historical average or to peers. A ratio above 1 indicates the company has more debt than equity and a ratio above 3 is considered high. Below 0.5 means the company has little debt and significant capacity to expand it.

Highlights and Quick Summary

  • Debt/Equity for the quarter ending June 30, 2023 was 0.0 (a -100.0% decrease compared to previous quarter)
  • Year-over-year quarterly Debt/Equity decreased by -100.0%
  • Annual Debt/Equity for 2022 was 0.01 (a 18.95% increase from previous year)
  • Annual Debt/Equity for 2021 was 0.01 (a Infinity% increase from previous year)
  • Annual Debt/Equity for 2020 was 0.0 (a -100.0% decrease from previous year)
Visit stockrow.com/DSGN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Debt/Equity of Design Therapeutics, Inc.

Most recent Debt/Equityof DSGN including historical data for past 10 years.

Interactive Chart of Debt/Equity of Design Therapeutics, Inc.

Design Therapeutics, Inc. Debt/Equity for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2023 0.0 0.01 – – –
2022 0.01 0.01 0.01 0.01 0.01
2021 0.01 0.01 0.0 0.0 0.01
2020 0.0 0.0 0.0 0.0 0.0
2019 – – – – -0.19

Business Profile of Design Therapeutics, Inc.

Sector: Healthcare
Industry: Biotechnology
© stockrow.com